SCHEMBL3025223

SCHEMBL3025223

Cc1cccc(-c2ccc3c(=O)[nH]c(-n4cccn4)nc3c2)c1

nearest known ligand 0.47

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
NPC1 O15118 3/20 0.47
RAB9A P51151 3/20 0.47
NLRP3 Q96P20 1/20 0.39
EGLN1 Q9GZT9 3/20 0.39
ERCC1 P07992 1/20 0.38
ERCC4 Q92889 1/20 0.38
PRKACA P17612 1/20 0.38
PRKACG P22612 1/20 0.38
PRKACB P22694 1/20 0.38
TGFBR1 P36897 1/20 0.38
SMN1; SMN2 Q16637 3/20 0.37
TSHR P16473 1/20 0.37
PBRM1 Q86U86 1/20 0.37
METAP2 P50579 1/20 0.37
ALDH1A1 P00352 3/20 0.37
MAPT P10636 2/20 0.37
KMT2A Q03164 1/20 0.37
LMNA P02545 2/20 0.37
GAA P10253 2/20 0.37
KDM4E B2RXH2 1/20 0.37

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL3036599 0.91 EGLN1 (0.48) NPC1RAB9AEGLN1ERCC1ERCC4
SCHEMBL3037229 0.88 EGLN1 (0.46) EGLN1ERCC1ERCC4PRKACAPRKACG
SCHEMBL3031131 0.88 PARP1 (0.41) NPC1RAB9ANLRP3EGLN1SMN1; SMN2
SCHEMBL3037043 0.83 EGLN1 (0.57) EGLN1TSHRALDH1A1LMNATNKS
SCHEMBL3038015 0.81 EGLN1 (0.49) EGLN1TGFBR1TNKSPARP1TNKS2
SCHEMBL3026678 0.81 TUBB4A (0.48) NPC1RAB9AEGLN1MAPTKMT2A
SCHEMBL3029769 0.80 EGLN1 (0.63) EGLN1
SCHEMBL3032031 0.80 EGLN1 (0.49) EGLN1ERCC1ERCC4MAPTMGLL
SCHEMBL3030790 0.78 TUBB4A (0.47) EGLN1SMN1; SMN2ALDH1A1MAPTKMT2A
SCHEMBL3025673 0.78 EGLN1 (0.43) NPC1RAB9AEGLN1SMN1; SMN2MAPT

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8937078-B2 Quinazolinones as prolyl hydroxylase inhibitors JANSSEN PHARMACEUTICA NV (BE) 2015-01-20 US disclosed
US-20100204226-A1 QUINAZOLINONES AS PROLYL HYDROXYLASE INHIBITORS JANSSEN PHARMACEUTICA NV (BE) 2010-08-12 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20100204226-A1 QUINAZOLINONES AS PROLYL HYDROXYLASE INHIBITORS P4HA1, EGLN3, EGLN2 NPC1 2457/4885RAB9A 1002/4885NLRP3 3226/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.